drugset / Trial / NCT00927615

Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO)

NCT00927615

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to investigate whether intracoronary bolus administration of abciximab is superior to intravenous bolus administration in improving myocardial perfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Timeline

Start
2008-09
Primary completion
2010-05
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abciximab Monoclonal antibody 0.25 mg/kg Intrathecal